Literature DB >> 32049051

Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP.

Yi Zhou1, Mingjian Fei1, Gu Zhang1, Wei-Ching Liang1, WeiYu Lin1, Yan Wu1, Robert Piskol1, John Ridgway1, Erin McNamara1, Haochu Huang1, Juan Zhang1, Jaehak Oh1, Jaina M Patel2, Diana Jakubiak1, Jeff Lau1, Beth Blackwood1, Daniel D Bravo1, Yongchang Shi1, Jianyong Wang1, Hong-Ming Hu2, Wyne P Lee1, Rajiv Jesudason1, Dewakar Sangaraju1, Zora Modrusan1, Keith R Anderson1, Søren Warming1, Merone Roose-Girma1, Minhong Yan3.   

Abstract

Clearance of apoptotic cells by macrophages prevents excessive inflammation and supports immune tolerance. Here, we examined the effect of blocking apoptotic cell clearance on anti-tumor immune response. We generated an antibody that selectively inhibited efferocytosis by phagocytic receptor MerTK. Blockade of MerTK resulted in accumulation of apoptotic cells within tumors and triggered a type I interferon response. Treatment of tumor-bearing mice with anti-MerTK antibody stimulated T cell activation and synergized with anti-PD-1 or anti-PD-L1 therapy. The anti-tumor effect induced by anti-MerTK treatment was lost in Stinggt/gt mice, but not in Cgas-/- mice. Abolishing cGAMP production in Cgas-/- tumor cells, depletion of extracellular ATP, or inactivation of the ATP-gated P2X7R channel also compromised the effects of MerTK blockade. Mechanistically, extracellular ATP acted via P2X7R to enhance the transport of extracellular cGAMP into macrophages and subsequent STING activation. Thus, MerTK blockade increases tumor immunogenicity and potentiates anti-tumor immunity, which has implications for cancer immunotherapy.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MerTK; P2X7R; STING; cGAS; cancer immunotherapy; efferocytosis; innate immunity; tumor-associated macrophage; type I IFN

Year:  2020        PMID: 32049051     DOI: 10.1016/j.immuni.2020.01.014

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  63 in total

Review 1.  Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy.

Authors:  Chuanhui Han; Anli Zhang; Zhida Liu; Casey Moore; Yang-Xin Fu
Journal:  Oncogene       Date:  2020-12-07       Impact factor: 9.867

2.  Structure-Aided Development of Small-Molecule Inhibitors of ENPP1, the Extracellular Phosphodiesterase of the Immunotransmitter cGAMP.

Authors:  Jacqueline A Carozza; Jenifer A Brown; Volker Böhnert; Daniel Fernandez; Yasmeen AlSaif; Rachel E Mardjuki; Mark Smith; Lingyin Li
Journal:  Cell Chem Biol       Date:  2020-07-28       Impact factor: 8.116

3.  Synthetic Matrix Scaffolds Engineer the In Vivo Tumor Immune Microenvironment for Immunotherapy Screening.

Authors:  Meghan J O'Melia; Adriana Mulero-Russe; Jihoon Kim; Alyssa Pybus; Deborah DeRyckere; Levi Wood; Douglas K Graham; Edward Botchwey; Andrés J García; Susan N Thomas
Journal:  Adv Mater       Date:  2022-01-31       Impact factor: 30.849

4.  Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.

Authors:  Diana Llopiz; Marta Ruiz; Leyre Silva; David Repáraz; Belén Aparicio; Josune Egea; Juan J Lasarte; Esther Redin; Alfonso Calvo; Matthew Angel; Jay A Berzofsky; David Stroncek; Pablo Sarobe
Journal:  Cancer Lett       Date:  2020-11-21       Impact factor: 8.679

Review 5.  The role of dendritic cells in cancer and anti-tumor immunity.

Authors:  Ariel E Marciscano; Niroshana Anandasabapathy
Journal:  Semin Immunol       Date:  2021-05-20       Impact factor: 11.130

Review 6.  Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.

Authors:  Juan Wang; Sumera Ilyas
Journal:  Expert Opin Investig Drugs       Date:  2020-12-28       Impact factor: 6.206

Review 7.  Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.

Authors:  Kyle M Garland; Taylor L Sheehy; John T Wilson
Journal:  Chem Rev       Date:  2022-02-02       Impact factor: 60.622

8.  AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia.

Authors:  Irene Tirado-Gonzalez; Arnaud Descot; Devona Soetopo; Aleksandra Nevmerzhitskaya; Alexander Schäffer; Ivan-Maximilano Kur; Ewelina Czlonka; Carolin Wachtel; Ioanna Tsoukala; Luise Müller; Anna-Lena Schäfer; Maresa Weitmann; Petra Dinse; Emily Alberto; Michèle C Buck; Jonathan Jm Landry; Bianka Baying; Julia Slotta-Huspenina; Jenny Roesler; Patrick N Harter; Anne-Sophie Kubasch; Jörn Meinel; Eiman Elwakeel; Elisabeth Strack; Christine Tran Quang; Omar Abdel-Wahab; Marc Schmitz; Andreas Weigert; Tobias Schmid; Uwe Platzbecker; Vladimir Benes; Jacques Ghysdael; Halvard Bonig; Katharina S Götze; Carla V Rothlin; Sourav Ghosh; Hind Medyouf
Journal:  Cancer Discov       Date:  2021-06-08       Impact factor: 39.397

9.  Macrophage-Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention.

Authors:  Xuefei Zhou; Xiangrui Liu; Leaf Huang
Journal:  Adv Funct Mater       Date:  2020-11-10       Impact factor: 18.808

Review 10.  The STING1 network regulates autophagy and cell death.

Authors:  Ruoxi Zhang; Rui Kang; Daolin Tang
Journal:  Signal Transduct Target Ther       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.